Brad Hively
Chairman
Starling Oncology, Inc. (STLN)Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Brad Hively
Brad Hively is recorded as Chairman at Starling Oncology, Inc. (STLN). Starling Oncology, Inc. reported in an 8-K filed June 12, 2023 that Brad Hively resigned as Chief Executive Officer, effective June 30, 2023. The proxy statement of Starling Oncology, Inc. reports total compensation of $1,215,190 for Brad Hively in fiscal 2023, including a base salary of $293,500. Disclosed compensation is on record for 4 fiscal years. Brad Hively has spoken on 6 earnings calls across 1 company, most recently for Starling Oncology, Inc. on May 10, 2023.
“On June 11, 2023, Brad Hively provided notice of his resignation as Chief Executive Officer of The Oncology Institute, Inc. (the "Company"), effective June 30, 2023 (the "Effective Date").”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Current
Start not stated–present
-
Start not stated–2023-04-28
Last confirmed by a filing; no departure on record
-
Start not stated–2023-06-30
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Starling Oncology, Inc.
Other people whose current roles at this company are on record from its filings.
- Daniel Virnich CEO, COO, Board Member
- Anne McGeorge Chairman
- Robert Carter CFO, Chief Accounting Officer
- Dr. Matt Miller COO
- Jeremy N. Castle COO
- Mark Huppelsheuser General Counsel
- Dr. Gregory Sorensen Board Member
- Dr. Jennifer Carter Board Member
- Dr. Mohit Kaushal Board Member
- Gabriel Ling Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2023 | Starling Oncology, Inc. (STLN) | — | $293,500 | $1,215,190 |
| 2022 | Starling Oncology, Inc. (STLN) | — | $579,208 | $6,629,723 |
| 2021 | Starling Oncology, Inc. (STLN) | — | $430,768 | $11,635,536 |
| 2020 | Starling Oncology, Inc. (STLN) | — | $400,000 | $611,400 |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.